Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03082287 · ClinicalTrials.gov registry record
ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool
A clinical trial, sponsored by American Laboratory Products Company.
- Completed
- Registry status
- 424
- Enrollment target
NCT03082287 is a clinical trial that has completed, run by American Laboratory Products Company. The registered enrollment target is 424 participants.
The verdict
NCT03082287 has completed, sponsored by American Laboratory Products Company.
- COMPLETED
- Registry status
- 424 participants
- Enrollment target
Study Summary
The ALPCO Calprotectin ELISA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture. This study will estimate the predictive values of a negative (NPV) and positive (PPV) test by utilizing the assay outcomes of the ALPCO Calprotectin ELISA.
Interventions
- DEVICE Fecal Calprotectin Level
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2019-10-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03082287
The ClinicalTrials.gov registry entry for NCT03082287 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Laboratory Products Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fecal Calprotectin Level is the first listed.
NCT03082287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03082287 about?
NCT03082287 is a clinical study titled "ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool". The ALPCO Calprotectin ELISA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases...
What is the current status of trial NCT03082287?
This trial is currently completed. The enrollment target is 424 participants. The study started on 2017-05-01. Estimated completion is 2019-10-25.
What interventions are being tested in trial NCT03082287?
The interventions under investigation include: Fecal Calprotectin Level (DEVICE).
Who is sponsoring clinical trial NCT03082287?
This trial is sponsored by American Laboratory Products Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.